BYSI BeyondSpring Inc

USD 2.08 -0.12 -5.454545
Icon

BeyondSpring Inc (BYSI) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 2.08

-0.12 (-5.45)%

USD 0.09B

0.01M

N/A

USD 19.33 (+829.33%)

Icon

BYSI

BeyondSpring Inc (USD)
COMMON STOCK | NSD
USD 2.08
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.09B

USD 19.33 (+829.33%)

USD 2.08

BeyondSpring Inc (BYSI) Stock Forecast

N/A

Based on the BeyondSpring Inc stock forecast from 0 analysts, the average analyst target price for BeyondSpring Inc is not available over the next 12 months. BeyondSpring Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BeyondSpring Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, BeyondSpring Inc’s stock price was USD 2.08. BeyondSpring Inc’s stock price has changed by -7.56% over the past week, -17.79% over the past month and +92.59% over the last year.

No recent analyst target price found for BeyondSpring Inc
No recent average analyst rating found for BeyondSpring Inc

Company Overview BeyondSpring Inc

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical ...Read More

28 Liberty Street, New York, NY, United States, 10005

36

December

USD

USA

Adjusted Closing Price for BeyondSpring Inc (BYSI)

Loading...

Unadjusted Closing Price for BeyondSpring Inc (BYSI)

Loading...

Share Trading Volume for BeyondSpring Inc Shares

Loading...

Compare Performance of BeyondSpring Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BYSI

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To BeyondSpring Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +4.34 (+0.88%) USD126.85B 31.94 20.00

ETFs Containing BYSI

Symbol Name BYSI's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About BeyondSpring Inc (BYSI) Stock

Stock Target Advisor's fundamental analysis for BeyondSpring Inc's stock is Bearish.

Unfortunately we do not have enough data on BYSI's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on BYSI's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on BYSI's stock to indicate if its overvalued.

The last closing price of BYSI's stock was USD 2.08.

The most recent market capitalization for BYSI is USD 0.09B.

Unfortunately we do not have enough analyst data on BYSI's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains BeyondSpring Inc's stock.

As per our most recent records BeyondSpring Inc has 36 Employees.

BeyondSpring Inc's registered address is 28 Liberty Street, New York, NY, United States, 10005. You can get more information about it from BeyondSpring Inc's website at https://beyondspringpharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...